The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

3 Jan 2017 12:31

RNS Number : 2100T
Motif Bio PLC
03 January 2017
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Motif Bio Plc.

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

No

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

No

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

No

An event changing the breakdown of voting rights

No

Other (please specify):

Change in Total Shares Outstanding

Yes

3. Full name of person(s) subject to thenotification obligation: iii

Invesco Limited

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

30 December 2016

6. Date on which issuer notified:

03 January 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

26%, 25%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary 0.1p Shares

 

49,416,000

49,416,000

49,416,000

49,416,000

25.24%

GB00BVVT4H71

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

49,416,000

25.24%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Invesco Asset Management Limited - 49,416,000

Proxy Voting:

10. Name of the proxy holder:

Invesco Limited

11. Number of voting rights proxy holder will ceaseto hold:

N/A

12. Date on which proxy holder will cease to holdvoting rights:

N/A

13. Additional information:

14. Contact name:

Philippa Holmes

15. Contact telephone number:

01491 417 447

 

Note: Annex should only be submitted to the FCA not the issuer

Annex: Notification of major interests in share

A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)

 

Contact address

(registered office for legal entities)

 

Phone number & email

 

Other useful information

(at least legal representative for legal persons)

 

B: Identity of the notifier, if applicable

Full name

 

Invesco (UK) Limited

Contact address

 

Perpetual Park, Perpetual Park Drive, Henley-on-Thames. Oxon. RG9 1HH

Phone number & email

 

01491 417000

Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)

C: Additional information

For notes on how to complete form TR-1 please see the FCA website.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFFFLDIVIID
Date   Source Headline
17th Apr 20187:00 amRNSPosting of UK Annual Report and Notice of AGM
11th Apr 20182:30 pmRNSIclaprim Abstracts for ECCMID 2018 Now Online
10th Apr 20187:00 amRNSFiscal Year 2017 Results
3rd Apr 20183:29 pmRNSHolding(s) in Company
3rd Apr 20187:00 amRNSInitiation of NDA Rolling Submission for Iclaprim
20th Mar 20187:00 amRNSMotif Bio Update on NDA Submission for Iclaprim
19th Mar 20187:00 amRNSMotif Bio to present at upcoming conferences
13th Mar 20183:55 pmRNSChange of Registered Office
7th Mar 201812:29 pmRNSExercise of Warrants
1st Mar 20187:00 amRNSGrant of share options to senior management
21st Feb 20187:00 amRNSMotif Bio to Present Iclaprim Data at ECCMID 2018
19th Feb 201812:53 pmRNSExercise of Warrants
2nd Feb 20183:00 pmRNSAppointment of Interim Chief Financial Officer
29th Jan 201812:07 pmRNSSecond Price Monitoring Extn
29th Jan 201812:02 pmRNSPrice Monitoring Extension
19th Jan 20187:00 amRNSFiling of U.S. Shelf Registration
16th Jan 20187:00 amRNSMotif Bio Receives Award from CF Foundation
12th Jan 20183:12 pmRNSHolding(s) in Company
11th Jan 20183:07 pmRNSHolding(s) in Company
8th Jan 20183:23 pmRNSExercise of Warrants
5th Jan 20187:00 amRNSMotif Bio to participate in panel discussion
22nd Dec 20177:01 amRNSNotes statement from Amphion Innovations
21st Dec 20171:00 pmRNSREVIVE-1 additional results published
14th Dec 20177:00 amRNSFiling of SEC Form F-3
28th Nov 20176:24 pmRNSHolding(s) in Company
17th Nov 20177:00 amRNSHolding(s) in Company
17th Nov 20177:00 amRNSExercise of Warrants
15th Nov 20177:00 amRNSSecures up to US$20 million debt financing
9th Nov 20172:40 pmRNSExercise of Warrants
6th Nov 201712:29 pmRNSHolding(s) in Company
18th Oct 20177:00 amRNSHolding(s) in Company
6th Oct 20171:20 pmRNSHolding(s) in Company
6th Oct 20177:00 amRNSNew Pre-Clinical Data for Iclaprim at IDWeek 2017
5th Oct 20179:57 amRNSHolding(s) in Company
4th Oct 20177:00 amRNSPositive Topline Results in Phase Three Study
29th Sep 20177:00 amRNSHalf-year Report
25th Sep 20177:01 amRNSHolding(s) in Company
15th Sep 20172:07 pmRNSiclaprim granted Orphan Drug Designation by US FDA
8th Sep 20171:00 pmRNSHost Investor and Analyst Event on September 20
31st Aug 20171:00 pmRNSCompany to present at conferences in September
30th Aug 20177:00 amRNSHolding(s) in Company
9th Aug 20177:00 amRNSREVIVE 2 Trial Last Patient Treated
18th Jul 20177:00 amRNSAmendment to Amphion Consultancy Agreement
6th Jul 20177:00 amRNSPRESENTING THREE POSTERS ON ICLAPRIM AT ID WEEK
28th Jun 201712:41 pmRNSExercise of warrants
27th Jun 20177:00 amRNSHolding(s) in Company
22nd Jun 20173:20 pmRNSResult of General Meeting
22nd Jun 20177:00 amRNSPresents at ID Week 2017
15th Jun 20175:42 pmRNSResults of Annual General Meeting
14th Jun 20177:00 amRNSPresentation at BIO International Convention

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.